F. Baffert

发表

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition

Eric Vangrevelinghe, Andrew L. Kung, James E. Bradner, 2011, The Journal of experimental medicine.

CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.

W. Sellers, N. Socci, A. Viale, 2015, Cancer cell.

Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts.

Gavin Thurston, G. Yancopoulos, D. McDonald, 2004, The American journal of pathology.

Angiopoietin-1 decreases plasma leakage by reducing number and size of endothelial gaps in venules.

D. McDonald, G. Thurston, F. Baffert, 2006, American journal of physiology. Heart and circulatory physiology.

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.

A. Letai, S. Sallan, M. Harris, 2015, Cancer cell.

The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.

D. Gingras, R. Béliveau, P. Poyet, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeutics.

J. Foekens, C. Schnell, J. Wood, 2008, Cancer research.

A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expression

N. Ebel, F. Hofmann, N. Hynes, 2019, PloS one.

Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805

D. Erdmann, J. Brueggen, P. Furet, 2010, Molecular Cancer Therapeutics.

Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling.

C. Kuo, D. McDonald, G. Thurston, 2006, American journal of physiology. Heart and circulatory physiology.

JAK1/2 and Pan-Deacetylase Inhibitor Combination Therapy Yields Improved Efficacy in Preclinical Mouse Models of JAK2V617F-Driven Disease

Ernesta Dammassa, N. Ebel, F. Hofmann, 2013, Clinical Cancer Research.

Long-Term and Sustained COMP-Ang1 Induces Long-Lasting Vascular Enlargement and Enhanced Blood Flow

D. McDonald, N. Mochizuki, B. Jeon, 2005, Circulation research.

Cancer Therapy : Preclinical JAK 1 / 2 and Pan-Deacetylase Inhibitor Combination Therapy Yields Improved Ef fi cacy in Preclinical Mouse Models of JAK 2 V 617 F-Driven Disease

Ernesta Dammassa, N. Ebel, F. Hofmann, 2013 .

Jak1/2 and Pan-deacetylase Inhibitor Combination Therapy Yields Improved Efficacy in Preclinical Mouse Models of Jak2 V617f -driven Disease Translational Relevance

Ernesta Dammassa, N. Ebel, F. Hofmann, 2022 .

Phase lb study of BEZ235 plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC).

J. Machiels, L. Dirix, L. Paz-Ares, 2014 .

Effects of prolonged exposure to hypoxia on morphological changes of endothelial cells plated on fibrin gel.

Y. Usson, F. Baffert, L. Tranqui, 2001, European journal of cell biology.

Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors.

Eric Vangrevelinghe, Clive McCarthy, Pascal Furet, 2010, Bioorganic & medicinal chemistry letters.

Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor

C. Schnell, D. Juric, J. Harding, 2018, Investigational New Drugs.

Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.

W. Sellers, R. Levine, F. Hofmann, 2012, Cancer discovery.

Genetic resistance to JAK 2 enzymatic inhibitors is overcome by HSP 90 inhibition

D. Erdmann, M. McKeown, J. Bradner, 2012 .

Gavin Thurston, D. McDonald, G. Thurston, 2004, Circulation research.

Angiopoietin 1 causes vessel enlargement, without angiogenic sprouting, during a critical developmental period

G. Yancopoulos, D. McDonald, N. Papadopoulos, 2005, Development.

Phase lb study of buparlisib (BKM120) plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC).

J. Machiels, L. Dirix, L. Paz-Ares, 2014 .

2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitors.

Eric Vangrevelinghe, Marc Lang, Pascal Furet, 2010, Bioorganic & medicinal chemistry letters.

Improved Efficacy Upon Combined JAK1/2 and Pan-Deacetylase Inhibition Using Ruxolitinib (INC424) and Panobinostat (LBH589) in Preclinical Mouse Models of JAK2V617F-Driven Disease

N. Ebel, M. Murakami, T. Radimerski, 2011 .

CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.

W. Sellers, N. Socci, A. Viale, 2015, Cancer cell.

J. Foekens, C. Schnell, J. Wood, 2008, Cancer research.

JAK1/2 and Pan-Deacetylase Inhibitor Combination Therapy Yields Improved Efficacy in Preclinical Mouse Models of JAK2V617F-Driven Disease

Ernesta Dammassa, N. Ebel, F. Hofmann, 2013, Clinical Cancer Research.